Brain-implant company Neuralink, owned by billionaire Elon Musk, announced on Wednesday that it now has a total of 21 participants enrolled in clinical trials worldwide, marking two years since it officially began human testing. This figure represents a major leap in the company’s efforts to prove the efficacy and safety of its revolutionary technology.
Article contents:
- Major expansion in clinical trials
- Mind control: From gaming to communication
- Safety record and regulatory collaboration
- The approval journey: From rejection to expansion
- The future: Hardware improvements and application expansion
- Conclusion
- Frequently asked questions
Major expansion in clinical trials
This announcement marks a notable increase from the 12 individuals the company stated last September had received its chips and were using them to control digital and physical tools through thought. The company said in a statement: “The primary objective of our expanding clinical trials is to better understand individual differences among patients and to refine both our devices and the overall surgical procedure for each participant.” This expansion reflects growing confidence in the system’s stability and its ability to work with a diverse range of users.
Mind control: From gaming to communication
The brain implant is designed to assist people suffering from complex medical conditions such as spinal cord injuries and quadriplegia. Preliminary results have shown remarkable success, with the first patient using the chip to play video games, browse the internet, post on social media platforms, and move a computer mouse cursor on a laptop, all simply by thinking. These capabilities afford patients a new level of independence and the ability to interact with the digital world without physical assistance.
Safety record and regulatory collaboration
In its statement, the company confirmed that it works closely with regulatory bodies and hospital sites to provide improved devices to participants. Most importantly, the company emphasized that it has maintained its current record of “zero device-related serious adverse events,” a gold standard in medical trials for implanted devices, especially those dealing with the sensitive human brain.
The approval journey: From rejection to expansion
The road was not easy; Neuralink began human trials only in 2024 after addressing major safety concerns raised by the U.S. Food and Drug Administration (FDA), which had rejected the company’s initial application in 2022. The ability to overcome these rigorous regulatory hurdles and reach 21 participants in a relatively short time is testament to the company’s seriousness and commitment to scientific and medical standards.
The future: Hardware improvements and application expansion
Neuralink is looking beyond mere cursor control. The long-term goal includes restoring movement to paralyzed limbs and, perhaps in the distant future, enhancing human cognitive capabilities. However, current focus remains on improving signal accuracy, minimizing invasiveness, and ensuring the chip’s long-term sustainability inside the body without degradation for years.
Conclusion
Neuralink’s trials offer hope to thousands of paralyzed individuals around the world. Although a long road remains before this technology becomes commercially available to everyone, rapid progress and current positive results indicate that the future of brain-machine interfacing is becoming a reality rather than science fiction.
Frequently asked questions
Question: How many participants are currently in Neuralink trials?
Answer: The company announced the enrollment of 21 participants in trials worldwide.
Question: What can participants do with the chip?
Answer: They can control computers, browse the internet, and play video games using only their thoughts.
Question: Is the chip safe?
Answer: The company confirms that no device-related serious adverse events have been recorded thus far in human trials.
